As The Dallas Morning News recently reported, women in the United States are “stocking up” on abortion pills out of fear these drugs (mainly misoprostol and mifepristone) will become hard to source due to looming restrictions.
Indeed, the Supreme Court will be ruling later this year on an appeal by the Fifth Circuit Court of Appeals limiting access by mail to mifepristone. The appellate court overturned a portion of the lower court ruling rescinding the Federal Drug Administration’s long-standing approval of mifepristone. It left intact the ability for women to acquire the drug by mail until a SCOTUS ruling. Also left intact, however, were some restrictions, including the provision that mifepristone only be administered in the presence of a physician and only through the seventh week of pregnancy rather than the 10th.
In all of this, pro-abortion activists and the medical community at large have minimized the inherent risks of a pregnant woman ingesting, unsupervised, the abortion drugs mifepristone and misoprostol. These risks are real. But they are, at this time, ignored, even by this country’s supposedly primary women’s medical support group, the American College of Obstetricians and Gynecologists (ACOG).
In the not-too-distant past, an obstetrician would be considered negligent if he or she did not weigh the well-known and well-documented risks associated with an undiagnosed ectopic pregnancy or the Rh status of a patient at the time of a miscarriage or abortion.
So what has changed? Certainly not the inherent risks of these two complications.
Risk of Undiagnosed Ectopic
